Flagship Biosciences Announces Biocom Membership

Broomfield, CO – April 3, 2019 — Flagship Biosciences, the advanced tissue data services company, today announced its membership in Biocom, the association representing the California life science industry. A Flagship representative will also serve on the Biocom Artificial Intelligence (AI) Committee.

“Flagship is pleased to be part of Biocom’s member network and its AI Committee,” said Trevor Johnson, Flagship Biosciences CEO. “Creating more informative data than traditional pathology methods and eliminating variability associated with typical analysis enables us to provide a critical understanding of tissue. We look forward to bringing increased accuracy and value to the members of Biocom.”

Flagship joins over 1,100 industry leaders and contract research organizations (CROs) that can now more easily place orders with Flagship through the Biocom’s member network. Offering advanced tissue analysis methods to reduce complexity and clarify cellular context allows Flagship to empower informed decision making in its clients’ drug development work.

“I’m delighted to represent Flagship Biosciences as Co-Chair of the Biocom Artificial Intelligence Committee,” said Sandra Martins, Flagship’s senior sales manager. “This opportunity allows Flagship to share our core expertise and experience as a pathway to help educate the membership of Biocom on the many ways AI can enhance our future.”

By bringing new insights and technology to existing tissue analysis, and scientific consultation to every project, Flagship’s team helps interpret analysis and describe tissue biology to more rapidly identify and provide the best data.

“I’m confident that Flagship will benefit from interacting with Biocom’s innovative members,” said Johnson. “I also look forward to sharing more about our technology and workflows that allow clients to advance drug development and accelerate therapies to patients.”

About Flagship Biosciences

Flagship Biosciences, Inc. is an advanced tissue analysis services company delivering science-based innovation for improved drug development. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathologists and scientists. It caters to pharmaceutical, biotechnology, and medical device companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. flagshipbio.com

About Biocom

Biocom works on behalf of over 1,100 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs. Biocom provides the strongest public voice for research institutions and life science companies that fuel the California economy. www.biocom.org.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

Flagship Biosciences Is Honored with a Best Practices Award

We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...

Flagship Biosciences hires Tom Turi, Ph.D. as CSO

Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...